First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child.
Grunewald
T G P
TGP
Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München; Laboratory of Functional Genomics and Transplantation Biology, Children's Cancer Research Center, Paediatric Oncology and Roman Herzog Comprehensive Cancer Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Damke
L
L
Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München.
Maschan
M
M
Department of Haematology, Federal Clinical Research Center for Paediatric Haematology, Oncology and Immunology, Moscow.
Petrova
U
U
Department of Haematology-1, Russian Children's Clinical Hospital, Moscow.
Surianinova
O
O
Department of Haematology, Yaroslavl Regional Children's Hospital, Yaroslavl.
Esipenko
A
A
Department of Haematology, Yaroslavl Regional Children's Hospital, Yaroslavl.
Konovalov
D
D
Department of Pathology, Federal Clinical Research Center for Paediatric Haematology, Oncology and Immunology, Moscow, Russian Federation.
Behrends
U
U
Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München.
Schiessl
J
J
Department of Pathology, Klinikum Schwabing.
Wörtler
K
K
Department of Radiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Burdach
S
S
Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München; Laboratory of Functional Genomics and Transplantation Biology, Children's Cancer Research Center, Paediatric Oncology and Roman Herzog Comprehensive Cancer Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
von Luettichau
I
I
Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München. Electronic address: irene.teichert-luettichau@lrz.tum.de.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D005240:Feasibility Studies; D006801:Humans; D008202:Lymphangioma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab